Presentations

Abstract

Introduction:

The treatment of intracranial aneurysms has a profound history, marked by notable breakthroughs in techniques and technology. Intrasaccular flow diverter devices emerged as a revolutionary paradigm shift in treating wide-neck intracranial aneurysms. These devices redirect blood flow away from the aneurysm, resulting in delayed clot formation and a gradual endothelialization of the parent vessel wall. Despite the breakthroughs, effective long-term treatment of wide-neck aneurysms remains an intricate challenge. Advancing modalities are actively being developed in endovascular therapies to facilitate efficient long-term benefits. Woven Endobridge (WEB) device is a recent and rapidly evolving innovation toward the treatment strategy of wide-neck intracranial aneurysms.

Body:

The Woven Bridge (WEB) embolization device is an intrasaccular flow diverter device designed to divert flow at the interface between the aneurysm and the parent artery. The device was first introduced in 2011 and has evolved in its design and uses over the past decade. It has been approved by the U.S. Food and Drug Administration (FDA) to treat wide-neck bifurcation aneurysms. Several pre-clinical and clinical trials have investigated the device's safety and efficacy, with promising results of long-term aneurysm stability and occlusion. The WEB device can be implanted in a shorter duration than other intrasaccular devices, providing the advantage of not requiring antiplatelet therapy post-procedure. It can be used to treat both ruptured and unruptured aneurysms. The device has undergone numerous modifications since it was first developed, guided by the insights from pre-clinical trials. Additional indications of the device have been identified in clinical studies, indicative of its evolving application.

Conclusion:

The WEB device is a pivotal tool in the ever-evolving landscape of intracranial aneurysm treatment. The device is unique in its innovation and indications, broadening the field of endovascular aneurysm management. As we continue to explore its potential, further investigation into the long-term association of recurrence and rupture rates would provide value for clinicians. It would also be beneficial to evaluate the rate of complications involving the WEB devices compared to those involving stents or clipping.